News
AI Dermatology Imaging Research: CAGR of 16. 3% during the forecast period
51+ min ago (56+ words) open PR. com AI Dermatology Imaging Research: CAGR of 16. 3% during the forecast period Press release from: QY Research Inc. Permanent link to this press release: You can edit or delete your press release AI Dermatology Imaging Research: CAGR of 16. 3% during…...
SCALE 2026: Dermatology Pearls for Clinical Practice
7+ hour, 24+ min ago (310+ words) EMJ This site is intended for healthcare professionals SCALE 2026: Dermatology Pearls for Clinical Practice THE Medical Dermatology Potpourri session at SCALE 2026, Nashville, Tennessee, USA, explored diverse topics in medical dermatology, providing scientific insights and clinical pearls for diagnosis and management,…...
Common De-Tan Myths That Are Doing More Harm Than Good
3+ hour, 53+ min ago (40+ words) femina. in - Common De-Tan Myths That Are Doing More Harm Than Good Femina's content is created, fact-checked, and reviewed by qualified writers, editors, clinicians, and other contributors....
Does Rose Petal Powder Really Brighten Skin? Here's What An Expert Says
3+ hour, 27+ min ago (479+ words) Rose petal powder is a popular addition to DIY skincare routines. It is mild, smells nice, easy to use, and is commonly utilised in homemade face masks and scrubs. Many people use it in hopes of achieving lighter skin, but…...
Sci Base Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes
3+ hour, 24+ min ago (190+ words) While Nevisense is already an established technology for the detection of melanoma and the assessment of skin barrier in conditions like atopic dermatitis, this new research expands its potential application into the field of geriatric dermatology and longevity science. Key…...
Alumis Reports 68% PASI 90 Response for Envudeucitinib in Psoriasis Trial
3+ hour, 30+ min ago (405+ words) The Clinical Trial Vanguard Alumis Reports 68% PASI 90 Response for Envudeucitinib in Psoriasis Trial Deucravacitinib captured roughly 68% PASI 90 response rates in pivotal trials and became the first oral TYK2 inhibitor approved for plaque psoriasis " yet Alumis is now reporting identical 68. 0% PASI 90 figures…...
Regeneron's Fianlimab Misses Statistical Significance in Melanoma Trial
3+ hour, 33+ min ago (394+ words) The Clinical Trial Vanguard Regeneron's Fianlimab Misses Statistical Significance in Melanoma Trial A 5. 1-month improvement in median progression-free survival " from 6. 4 months on pembrolizumab monotherapy to 11. 5 months on the high-dose fianlimab-cemiplimab combination " failed to cross the threshold of statistical significance, with…...
Electrosurgical Tangential Decortication for Severe Rhinophyma: A Case Report
10+ hour, 52+ min ago (158+ words) Rhinophyma represents the advanced phymatous stage of rosacea and is characterized by progressive sebaceous hyperplasia, connective tissue overgrowth, and vascular proliferation resulting in nasal deformity. Surgical intervention remains the definitive treatment for rhinophyma once fibrotic hypertrophy is established. Although CO…...
Skin cancer solutions closer
15+ hour, 19+ min ago (51+ words) Gympie Today Get the latest news to your email inbox FREE! Skin cancer solutions closer Following their successful launch in Maroochydore back in March 2017, Just Skin has been bringing their passion for providing medical [] Subscribe or Login to see the…...
Regeneron's LAG-3 inhibitor combo falls short in late-stage melanoma study
13+ hour, 11+ min ago (14+ words) First Word Pharma...